Document Detail


Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.
MedLine Citation:
PMID:  12459530     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Gorlin-Goltz syndrome, also referred to as naevoid basal cell carcinoma syndrome (NBCCS), is an autosomal dominant skin disease with complete penetrance and inconstancy of the four major findings: multiple naevoid basal cell carcinomas (BCCs), pits on palms and soles, skeletal abnormalities (for example, jaw cysts), and ectopic calcification. The treatment of multiple BCCs is still a matter of debate. We report three cases of multiple BCCs in Gorlin-Goltz syndrome treated with topical 5% imiquimod cream, an immune response modifier. Patients were successfully cleared of BCCs after treatment for 6-8 weeks. Histologically no apparent signs of BCC-persistence could be detected and no recurrences were detected during the 12 month follow up period.
Authors:
Eggert Stockfleth; Claas Ulrich; Axel Hauschild; Stephan Lischner; Thomas Meyer; Enno Christophers
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  European journal of dermatology : EJD     Volume:  12     ISSN:  1167-1122     ISO Abbreviation:  Eur J Dermatol     Publication Date:    2002 Nov-Dec
Date Detail:
Created Date:  2002-12-02     Completed Date:  2003-03-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9206420     Medline TA:  Eur J Dermatol     Country:  France    
Other Details:
Languages:  eng     Pagination:  569-72     Citation Subset:  IM    
Affiliation:
Department of Dermatology of the Charité, Humboldt University, Schumannstra e 20/21, 10117 Berlin, Germany. E.Stockfleth@web.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adult
Aged
Aminoquinolines / administration & dosage*
Basal Cell Nevus Syndrome / drug therapy*,  pathology
Biopsy, Needle
Dose-Response Relationship, Drug
Drug Administration Schedule
Face
Female
Follow-Up Studies
Humans
Immunohistochemistry
Male
Middle Aged
Sampling Studies
Skin Neoplasms / drug therapy*,  pathology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Aminoquinolines; 99011-02-6/imiquimod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Subclinical speckled perifollicular melanosis of the scalp.
Next Document:  Clinical and dermatoscopic diagnosis of small pigmented skin lesions.